




| Regimen | Lutetium-177 PSMA – Blood Results Protocol | | | | | | | | | | | | | | | | | | |
|--|--|---------------------|-------------------|-------|-------------|----|-----|-------------|-----|---------------------|-----------|-----|---------------------|---------|----|-----|------|----|--------|
| Indication | METASTATIC CASTRATION RESISTANT PROSTATE CANCER | | | | | | | | | | | | | | | | | | |
| Blood protocol and regime | <p>Patients receiving Lu 177 PSMA therapy are required to undergo regular blood tests. These are reviewed by the ARSAC licence holder responsible for the patients' care.</p> <p>All blood results are shared with the patient's oncologist. Where necessary the ARSAC licence holder shall escalate any abnormal results immediately to the named oncologist.</p> <p>The standard blood tests include:</p> <ul style="list-style-type: none"> • Full Blood Cell count • Liver Function tests • Urea and Electrolytes • Prostate Specific Antigen • Bone Profile <p>Bloods taken at GenesisCare Windsor are sent to TDL for analysis; the results are uploaded onto Mosaik and sent to the ARSAC licence holders medical secretary; the secretary will review the results in line with the agreed parameters (outlined below). Any bloods outside of these parameters shall be escalated to the ARSAC licence holder for immediate attention and action.</p> <p>All blood results that do not require immediate attention will be shared with the ARSAC licence holder within 24 hours of their notification. Subsequent review and acknowledgement of these results by the ARSAC licence holder shall be relayed back to the medical secretary within a further 24 hours.</p> <p>The medical secretary will record all communications in MSQ.</p> | | | | | | | | | | | | | | | | | | |
| Frequency | <p>Bloods are taken:</p> <ol style="list-style-type: none"> 1. Two weeks prior to the 1st Cycle (baseline) 2. On the day of each cycle of therapy and follow-up Ga-PSMA PET/CT 3. At two-weekly intervals between cycles | | | | | | | | | | | | | | | | | | |
| Additional information: | If bloods results are outside of the agreed parameters, then weekly checks may be instigated by the ARSAC licence holder or referring oncologist. | | | | | | | | | | | | | | | | | | |
| Standard limits for blood results | <p>Blood parameters should be no lower than as indicated in the following table. Blood results lower than this should be notified to the ARSAC licence holder immediately.</p> <table border="1" data-bbox="427 1547 1214 1816"> <thead> <tr> <th>Test name</th> <th>Minimum threshold</th> <th>Units</th> </tr> </thead> <tbody> <tr> <td>Haemoglobin</td> <td>80</td> <td>g/L</td> </tr> <tr> <td>Neutrophils</td> <td>1.5</td> <td>x10⁹/L</td> </tr> <tr> <td>Platelets</td> <td>100</td> <td>x10⁹/L</td> </tr> <tr> <td>Albumin</td> <td>25</td> <td>g/L</td> </tr> <tr> <td>eGFR</td> <td>40</td> <td>mL/min</td> </tr> </tbody> </table> | Test name | Minimum threshold | Units | Haemoglobin | 80 | g/L | Neutrophils | 1.5 | x10 ⁹ /L | Platelets | 100 | x10 ⁹ /L | Albumin | 25 | g/L | eGFR | 40 | mL/min |
| Test name | Minimum threshold | Units | | | | | | | | | | | | | | | | | |
| Haemoglobin | 80 | g/L | | | | | | | | | | | | | | | | | |
| Neutrophils | 1.5 | x10 ⁹ /L | | | | | | | | | | | | | | | | | |
| Platelets | 100 | x10 ⁹ /L | | | | | | | | | | | | | | | | | |
| Albumin | 25 | g/L | | | | | | | | | | | | | | | | | |
| eGFR | 40 | mL/min | | | | | | | | | | | | | | | | | |
| Comments | If Potassium or Calcium results are reported as high or low on any result and highlighted in red on that report then the medical secretary or member of the Theranostic team shall escalate the result to the ARSAC licence holder immediately. | | | | | | | | | | | | | | | | | | |

Revision History

| | | |
|-----------------------------------|--|---|
| Document Title | Clinical Protocol: Management of Blood results in Lu PSMA therapy | |
| Document number | THE-PRO-122 | |
| Approval date | 14 th September 2020 | |
| Written by | Anita Harte Head of Theranostics and Imaging |  |
| Checked by | Richard Schorstein Head of Nursing |  |
| Authorised and approved by | Dr Yong Du - Clinical Director Nuclear Medicine and Theranostics |  |
| Review date | Every 3 years or if any significant changes | |
| Version Number | 2.0 | |
| Summary of changes | V2.0 - Nov 2021 - Bone profile added, specification of GC Windsor, some rewording – Matt Patterson, Lead NMT | |